Cogent Biosciences (COGT) reported updated results Monday from the open-label extension portion of the SUMMIT clinical trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis.
The biotech firm said the clinical results focus on 27 patients in the open-label extension who were treated with the once-daily 100 mg dose of bezuclastinib.
Cogent said that at 24 weeks of treatment, 31% of patients had reduced or discontinued best supportive care medications. It also said Bezuclastinib "showed rapid, deep, and sustained reductions" in serum tryptase during 24 weeks of treatment.
Shares of Cogent Biosciences were down 19% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。